相似文献
1
Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment.聚（ADP - 核糖）聚合酶抑制剂：晚期前列腺癌治疗的新视野。
Investig Clin Urol. 2023 Sep;64(5):419-421. doi: 10.4111/icu.20230185.
2
PARP Inhibition in Prostate Cancer: A Promising Approach.
Oncology (Williston Park). 2016 May;30(5):393-4, 485.
3
PARP inhibitor response in prostate cancer.PARP抑制剂在前列腺癌中的反应
Nat Rev Urol. 2023 Mar;20(3):130. doi: 10.1038/s41585-023-00735-0.
4
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.用于治疗晚期种系BRCA2突变前列腺癌的聚（ADP-核糖）聚合酶（PARP）抑制剂
Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
5
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?在转移性前列腺癌中，将聚（ADP-核糖）聚合酶（PARP）抑制剂添加到雄激素受体信号传导抑制剂中：我们遗漏了什么？
Ann Oncol. 2023 Sep;34(9):729-731. doi: 10.1016/j.annonc.2023.06.008. Epub 2023 Jul 3.
6
Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.非 NAD 类似物的 PARP-1 抑制剂在前列腺癌治疗中的应用。
Biochem Pharmacol. 2019 Sep;167:149-162. doi: 10.1016/j.bcp.2019.03.021. Epub 2019 Mar 15.
7
PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.前列腺癌中的聚 ADP 核糖聚合酶抑制剂：临床前原理与当前临床开发。
Genes (Basel). 2019 Jul 26;10(8):565. doi: 10.3390/genes10080565.
8
Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.前列腺癌中 PARP 抑制剂的反应预测生物标志物和药物组合。
Acta Pharmacol Sin. 2021 Dec;42(12):1970-1980. doi: 10.1038/s41401-020-00604-1. Epub 2021 Feb 15.
9
Improving outcome in patients with prostate and kidney cancer: heading in the right direction?改善前列腺癌和肾癌患者的治疗结果：是否朝着正确的方向前进？
Curr Opin Support Palliat Care. 2018 Sep;12(3):323-324. doi: 10.1097/SPC.0000000000000368.
10
Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.超越晚期前列腺癌中的雄激素受体 对《转移性前列腺癌中的DNA修复缺陷与奥拉帕利》的述评
Urology. 2016 Mar;89:10-1. doi: 10.1016/j.urology.2015.12.002. Epub 2015 Dec 23.
引用本文的文献
1
Arthritis increases the risk of prostate cancer: Results from the National Health and Nutrition Examination Survey 2005-2018 and two-sample Mendelian randomization analysis.关节炎会增加患前列腺癌的风险：来自2005 - 2018年美国国家健康与营养检查调查以及两样本孟德尔随机化分析的结果。
Investig Clin Urol. 2025 May;66(3):215-226. doi: 10.4111/icu.20240313.
本文引用的文献
1
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.阿比特龙联合奥拉帕利治疗转移性去势抵抗性前列腺癌
NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.
2
Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer.液体活检在评估去势抵抗性前列腺癌基因组改变中的实际应用
Cancers (Basel). 2023 May 20;15(10):2847. doi: 10.3390/cancers15102847.
3
Genomic and phenotypic heterogeneity in prostate cancer.前列腺癌的基因组和表型异质性。
Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16.
4
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
5
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.前列腺癌中雄激素受体信号传导与PARP途径之间的合成致死性。
Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.
6
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.转移性前列腺癌中的DNA修复缺陷与奥拉帕利
N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
Zotero 插件